Phase II study of amonafide in patients with recurrent glioma

Ralph Levitt, Jan C. Buckner, Terrence L. Cascino, Patrick A. Burch, Roscoe F. Morton, Mark W. Westberg, Richard M. Goldberg, James G. Gallagher, Judith R. O'Fallon, Bernd W. Scheithauer

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Amonafide, a novel imide derivative with broad preclinical antitumor activity, achieves significant cerebrospinal fluid levels in animal models. In order to test its antitumor activity in patients with recurrent diffuse infiltrative glioma of the astrocytic and oligodendroglial type, we performed a phase II clinical trial. Of the 22 eligible and evaluable patients treated, 2 (9%) experienced tumor regression lasting more than one year. No other patients experienced tumor regression; one remained stable more than six months. Toxicities consisted primarily of myelosuppression, vomiting, and venous irritation at the infusion site. We conclude that amonafide has minimal activity in recurrent glioma patients. Further investigations are not warranted in this study population.

Original languageEnglish (US)
Pages (from-to)87-93
Number of pages7
JournalJournal of neuro-oncology
Issue number1
StatePublished - Feb 1995


  • amonafide
  • astrocytoma
  • brain neoplasm
  • chemotherapy
  • glioma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research


Dive into the research topics of 'Phase II study of amonafide in patients with recurrent glioma'. Together they form a unique fingerprint.

Cite this